Citigroup Maintains Buy on Guardant Health, Raises Price Target to $215
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Patrick Donnelly maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $150 to $215.
Citigroup analyst Patrick Donnelly maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $150 to $215.